Kevin Young

Kevin Young joined Gilead Sciences in 2004 as Executive Vice President of Commercial Operations. Mr. Young is a 29-year veteran of the biopharmaceutical industry, with a career that spans a variety of therapeutic categories including cardiology, oncology, rheumatology, hepatitis and HIV/AIDS.

He previously held positions at Amgen, Inc. and AstraZeneca Pharmaceuticals (formerly ICI Pharmaceuticals). During his 12 years at Amgen, Mr. Young held a number of positions in Europe and the United States, most recently as Head of the U.S. Inflammation Business Unit leading the re-launch of Enbrel® following the acquisition of Immunex Corporation.

In 2011, Mr. Young was appointed Commander of The British Empire, one of Great Britain’s highest civilian honors, in recognition of his service to the healthcare and pharmaceutical industries.

Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool John Moores University and Nottingham University in England and has completed the Executive Program at the University of Michigan.

Kevin Young is the Executive Vice President, Commercial Operations at Gilead Sciences, based in United States, North America. With a background in Biotechnology, Kevin Young has a rich history of leadership and innovation.Kevin Young studied BA Sports Science and Exercise at Liverpool John Moores University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.